The IPO concluded its public bidding on August 1, receiving an overwhelming subscription of 41 times the offered shares.

Chemours is at a cyclical low, presenting a buying opportunity ahead of expected 2Q25 revenue growth. Click here to read an ...

Operating expenses decreased sharply compared to Q2 2024, supporting a cash runway into the second quarter of 2026. - Dose expansion enrollment was completed for the lead product in its main clinical ...

HOUSTON, TX / ACCESS Newswire / August 4, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an ...